– UK, Derbyshire – N4 Pharma Plc (LON: N4P), the specialist pharmaceutical company developing Nuvec, a novel delivery system for vaccines and cancer treatments, today announced the appointment of Dr John Chiplin as Non-Executive Chairman of the Company, and the appointment of Dr Chris Britten as a Non-Executive Director of the Company.
In addition, Paul Titley has decided to step down from the board for personal reasons and Dr David Templeton, formerly Chairman, will now serve as a part-time Executive Director in order to manage the technical aspects of the Company’s Nuvec programme.
Nigel Theobald, CEO, commented: “I am delighted that John and Chris have agreed to join our board. Their considerable experience will strengthen our team and will provide a strong boost to our commercialisation plans for Nuvec.
“Equally, I am delighted that David is now able to take an executive role to oversee all technical aspects of our Nuvec programme and any other assets we may bring into the Company’s portfolio.
“I would also like to thank Paul for all the time and support he has provided me personally to help grow the Company from its early origins.”
All board changes are effective immediately.
About Dr John Chiplin
Dr John Chiplin has significant operational, investment and transaction experience in the life science and technology industries. Between 1995 and 2014, Dr Chiplin served as CEO of three leading publicly listed software, biotechnology, and cancer immunotherapy companies in the US. Based in London, Dr Chiplin’s current board roles include Adalta, Cynata, Regeneus and Scancell Holdings plc (AIM: SCLP). He is also Managing Director of Newstar Ventures Ltd, an international private equity firm focused on emerging companies.
About Dr Chris Britten
Dr Chris Britten is an experienced pharmaceutical executive and is currently Head of M&A at Neuraxpharm, a privately-owned European CNS specialty pharmaceutical company. He has over 20 years’ experience in R&D, corporate development and investment banking. Previous roles include Global Head of M&A at Sandoz, Managing Director at Torreya Partners, Head of Business Development at Sanofi Pasteur MSD and Director, Life Sciences at Deloitte Corporate Finance. Chris also spent many years at GSK in both drug discovery and corporate development.
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec.
N4 Pharma’s business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through preclinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.
For more information: https://www.n4pharma.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.